It should be noted that most of the actual knowledge on mTOR pathway in DN was obtained by using pharmacological inhibition of mTORC1 with rapamycin; nevertheless, it has been suggested by studies using animal models that mTORC2 activation also has a role in DN, which should be further exploited. The gene discussed is MTOR; the disease is liver dysplastic nodule.